Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

A team of researchers from Case Western Reserve School of Medicine has discovered how the cancer-related protein Bcl-2 signals cancer cells to live longer.

14 Feb 2014

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

14 Feb 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.

30 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

22 Jan 2014

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.

22 Jan 2014

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Janssen-Cilag International NV today announced the early stopping of PCYC-1112-CA, the Phase 3 study of ibrutinib in the treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, based on the recommendation of an Independent Data Monitoring Committee, which concluded that the study showed a significant difference in progression-free survival as compared to the control, the primary endpoint of the study.

8 Jan 2014

Study suggests that ROR1 could be an important therapeutic target for patients with CLL

Researchers at the University of California, San Diego School of Medicine report that an oncogene dubbed ROR1, found on chronic lymphocytic leukemia (CLL) B cells but not normal adult tissues, acts as an accelerant when combined with another oncogene, resulting in a faster-developing, more aggressive form of CLL in mice.

3 Jan 2014

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

20 Dec 2013

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

12 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

Chronic Lymphocytic Leukemia News and Research

Further Reading

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Study suggests that ROR1 could be an important therapeutic target for patients with CLL

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News